AI and Data Analyst, Biostatistician
PhD, MS, BS
Yuliya Karpievitch is an Artificial Intelligence and Data Scientist. Her research focuses on computational models in respiratory conditions such as cystic fibrosis, bronchiectasis and asthma. Yuliya uses long-read Nanopore sequencing to obtain a picture of the lung microbiome and patient’s response to the microbiome and uses artificial intelligence (AI) to decipher the complex microbiome-microbiome-host interactions.
Yuliya is leading an AI and Data Science team in drug screening and computed tomography (CT) scan analyses automation using AI. Her Data Science part of the team is leading Bayesian analyses of clinical trials and provides statistical support to the Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF) and Airway Epithelial Research Team (EPIC) teams.
- Projects
-
Publications
March 2024
A phase I clinical trial assessing the safety, tolerability, and pharmacokinetics of inhaled ethanol in humans as a potential treatment for respiratory tract infections
Current treatments for respiratory infections are severely limited. Ethanol's unique properties including antimicrobial, immunomodulatory, and surfactant-like activity make it a promising candidate treatment for respiratory infections if it can be delivered safely to the airway by inhalation. Here, we explore the safety, tolerability, and pharmacokinetics of inhaled ethanol in a phase I clinical trial.
Published research Infectious Diseases P4 Respiratory Health for Kids Subsite: Walyan BREATH Respiratory viral infectionsJanuary 2024Thoracic electrical impedance tomography identifies heterogeneity in lungs associated with respiratory disease in cattle. A pilot study
Respiratory disease in cattle is a significant global concern, yet current diagnostic methods are limited, and there is a lack of crush-side tests for detecting active disease. To address this gap, we propose utilizing electrical impedance tomography (EIT), a non-invasive imaging technique that provides real-time visualization of lung ventilation dynamics.
Published research P4 Respiratory Health for Kids Subsite: Walyan Respiratory viral infections Lung functionJuly 2023Interferon β-1a ring prophylaxis to reduce household transmission of SARS-CoV-2: a cluster randomised clinical trial
Accumulating evidence indicates that an early, robust type 1 interferon (IFN) response to SARS-CoV-2 is important in determining COVID-19 outcomes, with an inadequate IFN response associated with disease severity. Our objective was to examine the prophylactic potential of IFN administration to limit viral transmission.
Published research Infectious Diseases Airway Epithelial Research P4 Respiratory Health for Kids Subsite: Walyan Systems Vaccinology COVID-19August 2022Lipopolysaccharide-induced interferon response networks at birth are predictive of severe viral lower respiratory infections in the first year of life
Appropriate innate immune function is essential to limit pathogenesis and severity of severe lower respiratory infections (sLRI) during infancy, a leading cause of hospitalization and risk factor for subsequent asthma in this age group.
Published research Early Childhood Development Pregnancy and Early Life Immunology Human Immunology P4 Respiratory Health for Kids Respiratory viral infectionsMay 2022AI-Driven Cell Tracking to Enable High-Throughput Drug Screening Targeting Airway Epithelial Repair for Children with Asthma
The airway epithelium of children with asthma is characterized by aberrant repair that may be therapeutically modifiable. The development of epithelial-targeting therapeutics that enhance airway repair could provide a novel treatment avenue for childhood asthma.
Published research Airway Epithelial Research P4 Respiratory Health for Kids Subsite: Walyan -
Education and Qualifications